Intellia Therapeutics (NTLA) PT Raised to $70 at BMO Capital

BMO Capital analyst Kostas Biliouris raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $70.00 (from $62.00) while maintaining a Outperform rating.

The analyst commented, "Pipeline is progressing with key 2024 catalysts: (1) NTLA-2002 PhI/PhII data in ~mid-2024; (2) Clinical data for all NTLA-2001 patients (N=72) in 2H24; (3) NTLA-2001 redosing data (N=3) in 2H24. We are excited about the NTLA-2001 opportunity in ATTR-PN given the short development timeline (approval in ~2027E), attractiveness of gene editing in ATTR-PN (vs. ATTR-CM) given less alternative treatments (no Tafamidis approval) and earlier symptom onset. We add ATTR-PN to our model, PT to $70."

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho
• Cerebras Systems (CBRS) PT Lowered to $300 at Mizuho